[Antisecretory therapy strategy for patients with bleeding and perforated gastroduodenal ulcers].
Evseev
M A
MA
Ivakhov
G B
GB
Golovin
R A
RA
D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D010439:Peptic Ulcer Perforation / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D010890:Pirenzepine / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000863:Antacids; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D010890:Pirenzepine; D015738:Famotidine; D009853:Omeprazole